AN2 Therapeutics plans Phase 1 study of hypophosphatasia drug for second half of 2027
ANTX•AN2 Therapeutics selected oral ENPP1 inhibitor AN2-504661 as a development candidate for hypophosphatasia and plans a Phase 1 study in the second half of 2027.
1. Drug development plans
AN2 Therapeutics selected AN2-504661, an oral ENPP1 inhibitor, as a development candidate for hypophosphatasia. The company reported preclinical efficacy in animal models, favorable drug properties and an encouraging safety profile, and plans a Phase 1 study for the second half of 2027.
